Skip to main content
. 2018 Sep 6;3(17):e122799. doi: 10.1172/jci.insight.122799

Figure 4. Key signaling pathway deregulation and survival outcomes in metastatic HPV-associated oropharyngeal cancer.

Figure 4

(A) Mutational signaling of the PI3K/MTOR/AKT pathway and its dysregulation in HPV+ oropharyngeal carcinoma. Each box represents the mutational frequency of gene(s) associated with a particular pathway protein. Somatic alteration frequencies among a metastatic HPV+ oropharyngeal cancer cohort (left, n = 42) and the TCGA and University of Chicago HPV+ oropharyngeal cancer cohorts (right, n = 87) are shown. Blue shading represents a dominance of inactivating mutations and red shading, activating mutations. (B) Key mutational frequencies among subgroups arranged by overall survival (OS) and time to recurrence (TTR), in months. Mutational frequencies (%) are not mutually exclusive and therefore columns total greater than 100% in some cases. (C) OS among metastatic HPV+ oropharyngeal cancer patients separated by PI3K pathway alteration status. *P < 0.05, log-rank testing.